The activity of sunitinib against gastrointestinal stromal tumor seems to be distinct from its antiangiogenic effects.
Seandel
Marco
M
Shia
Jinru
J
Linkov
Irina
I
Maki
Robert G
RG
Antonescu
Cristina R
CR
Dupont
Jakob
J
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002455:Cell Division / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005260:Female; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery*; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D008875:Middle Aged; D018365:Neoplasm, Residual / Q000601:surgery; D010770:Phosphotransferases / Q000037:antagonists & inhibitors; D011758:Pyrroles / Q000627:therapeutic use*; D000077210:Sunitinib; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D007211:Indoles; D011758:Pyrroles; D010770:Phosphotransferases; D000077210:Sunitinib